Human Microbiome Market to Surpass US$ 201.5 Billion by 2026 with leading: Enterome Bioscience, Merck, Osel, Yakult Honsha, Metabiomics Corporation, AOBiome LLC, uBiome

Global Human Microbiome Market, by Product Type (Foods, Diagnostic Devices/Kits, Drugs, and Others), by Application (Therapeutics and Diagnostics), by Disease Indication (Gastrointestinal Disorders, Metabolic Disorders, Women Health, Cancer, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 46,913.4 million in 2017, and is projected to exhibit a CAGR of 17.5% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.

High number of collaboration activities between key players and academia

Increasing number of collaboration activities between various players in the market and between different players and research institutes is expected to aid in the expansion and development of novel medicines for variety of diseases. For instance, in 2017, AOBiome secured US$ 30 million investment for advancing clinical research on systemic and topical inflammatory disorders using novel bacterial platform from iCarbonX. It is evident that such efforts are accelerating the research and development of microbiome platform.

For In depth Information Get FREE Sample Copy of this Report at: https://www.coherentmarketinsights.com/insight/request-sample/182

Key players operating in the global human microbiome market include:
1. Enterome Bioscience
2. Yakult Honsha Co., Ltd.
3. DuPont
4. Metabiomics Corporation
5. ViThera Pharmaceuticals
6. Second Genome Inc.
7. AOBiome LLC
8. Seres Therapeutics
9. uBiome, Inc.
10. Rebiotix, Inc.
11. Synthetic Biologics, Inc.
12. MicroBiome Therapeutics LLC
13. Vedanta BioSciences
14. Osel, Inc.
15. Merck & Co., Inc.

Similarly, in 2017, Stanford University School of Medicine and Vedanta Biosciences Inc. entered in research collaboration to focus on food allergies in children and on patients with C. difficile infection or graft-versus-host disease

Browse 36 Market Data Tables and 35 Figures spread through 220 Pages and in-depth TOC on ‘Human Microbiome Market’- Global Forecast to 2026, by Product Type (Foods, Diagnostic Devices/Kits, Drugs, and Others), by Application (Therapeutics, and Diagnostics), by Disease Indication (Gastrointestinal Disorders, Metabolic Disorders, Women Health, Cancer, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) To know the latest trends and insights prevalent in the Human Microbiome market, click the link below:

https://www.coherentmarketinsights.com/market-insight/human-microbiome-market-182

Growing incidence of disease conditions in which human microbiome product is used. According to data given by Centre for Disease Control and Prevention in October 2017, Clostridium difficile infection (CDI) is one of the most common healthcare-associated infections in the China and Hong Kong, affecting around 36.1 cases/100,000 person in 2014, an annual increase of 26%. According to study published in Clinical Infectious Disease journal in 2015, about 25% to 33% of antibiotic-associated diarrhea and 90% of pseudomembranous enteritis are caused by CDI.

Key Takeaways of the Human Microbiome Market:

-The global human microbiome market is expected to exhibit a CAGR of 17.5% over the forecast period, owing to increasing prevalence of cardiopulmonary conditions, cancer, and renal diseases.

-Among product type, the foods segment held a dominant position in the human microbiome market in 2017, owing to high adoption of probiotics-based food and beverages for maintaining balance of microbiomes

-Among disease type, cancer disease held a dominant position in the human microbiome market in 2017. In September 2018, World Health Organization (WHO), stated that cancer is the second largest cause of deaths globally.

-Among application, diagnostics segment held a dominant position in the human microbiome market in 2017, as emergence of diagnosis in early stage of cancer and other diseases is proven to be beneficial in disease management.

-Key players operating in the global human microbiome market include Enterome Bioscience, Yakult Honsha Co., Ltd., DuPont, Metabiomics Corporation, ViThera Pharmaceuticals, Second Genome Inc., AOBiome LLC, Seres Therapeutics, uBiome, Inc., Rebiotix, Inc., Synthetic Biologics, Inc., MicroBiome Therapeutics LLC, Vedanta BioSciences, Osel, Inc., and Merck & Co., Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.